Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and Histiocytosis, Langerhans-Cell

imatinib mesylate has been researched along with Histiocytosis, Langerhans-Cell in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abla, O; Weitzman, S1
Goerdt, S; Krömer-Olbrisch, T; Kurzen, H; Mohme, H; Stadler, R; Wagner, C1
Amin, HM; Garrido-Laguna, I; Janku, F; Kurzrock, R; Trent, JC; Yang, D1
Baumann, M; Cerny, T; Koeberle, D; Sommacal, A1
Insabato, L; Montella, L; Palmieri, G1

Other Studies

5 other study(ies) available for imatinib mesylate and Histiocytosis, Langerhans-Cell

ArticleYear
Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
    Hematology. American Society of Hematology. Education Program, 2015, Volume: 2015

    Topics: Clinical Trials as Topic; Erdheim-Chester Disease; Histiocytosis, Langerhans-Cell; Humans; Imatinib Mesylate; Indoles; Inflammation; MAP Kinase Kinase 1; MAP Kinase Signaling System; Mutation; Phosphorylation; Prospective Studies; Proto-Oncogene Mas; Proto-Oncogene Proteins B-raf; Recurrence; Risk; Sulfonamides; Vemurafenib

2015
Langerhans cell histiocytosis: treatment failure with imatinib.
    Archives of dermatology, 2009, Volume: 145, Issue:8

    Topics: Adult; Aged, 80 and over; Benzamides; Histiocytosis, Langerhans-Cell; Humans; Imatinib Mesylate; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Skin Diseases; Treatment Failure; Young Adult

2009
Response of histiocytoses to imatinib mesylate: fire to ashes.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzamides; Brain Neoplasms; Diagnosis, Differential; Drug Administration Schedule; Erdheim-Chester Disease; Female; Genes, abl; Histiocytosis, Langerhans-Cell; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Mutation; Piperazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Tomography, X-Ray Computed; Treatment Outcome

2010
Langerhans cell histiocytosis with central nervous system involvement--complete response to 2-chlorodeoxyadenosine after failure of tyrosine kinase inhibitor therapies with sorafenib and imatinib.
    Hematological oncology, 2012, Volume: 30, Issue:2

    Topics: Adult; Antineoplastic Agents; Benzamides; Benzenesulfonates; Central Nervous System Diseases; Cladribine; Histiocytosis, Langerhans-Cell; Humans; Imatinib Mesylate; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sorafenib

2012
Imatinib mesylate for cerebral Langerhans'-cell histiocytosis.
    The New England journal of medicine, 2004, Sep-02, Volume: 351, Issue:10

    Topics: Adult; Benzamides; Brain Diseases; Enzyme Inhibitors; Female; Histiocytosis, Langerhans-Cell; Humans; Imatinib Mesylate; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Skin

2004